Below are the most recent publications written about "Androgen Antagonists" by people in Profiles.
-
Mínguez-Alarcón L, Burns J, Williams PL, Korrick SA, Lee MM, Bather JR, Kovalev SV, Sokolov SA, Lebedev AT, Smigulina L, Ghayda RA, Koch HM, Sergeyev O, Hauser R. Urinary phthalate metabolite concentrations during four windows spanning puberty (prepuberty through sexual maturity) and association with semen quality among young Russian men. Int J Hyg Environ Health. 2022 Jun; 243:113977.
-
Burns JS, Sergeyev O, Lee MM, Williams PL, Mínguez-Alarcón L, Plaku-Alakbarova B, Sokolov S, Kovalev S, Koch HM, Lebedev AT, Hauser R, Korrick SA. Associations of prepubertal urinary phthalate metabolite concentrations with pubertal onset among a longitudinal cohort of boys. Environ Res. 2022 Sep; 212(Pt A):113218.
-
Nigro MC, Mollica V, Marchetti A, Cheng M, Rosellini M, Montironi R, Cheng L, Massari F. Current androgen receptor antagonists under investigation for resistant prostate cancer. Expert Rev Anticancer Ther. 2022 Feb; 22(2):191-202.
-
Lau HD, Clark M. Metastatic squamous cell carcinoma transformed from prostatic adenocarcinoma following androgen deprivation therapy: A case report with clinicopathologic and molecular findings. Diagn Cytopathol. 2020 Dec; 48(12):E14-E17.
-
Di Nunno V, Santoni M, Gatto L, Mollica V, Massari F. Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. Lancet 2018;392:2353-66: Metastatic Hormone-naïve Prostate Cancer: A Multimodal Approach for a Heterogeneous Disease. Eur Urol Oncol. 2020 06; 3(3):390.
-
Ciccarese C, Santoni M, Massari F. Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer. N Engl J Med. 2016 01 21; 374(3):286.
-
Ko EC, Liu JT, Stone NN, Stock RG. Association of early PSA failure time with increased distant metastasis and decreased survival in prostate brachytherapy patients. Radiother Oncol. 2014 Feb; 110(2):261-7.
-
Schoenfeld JD, Margalit DN, Kasperzyk JL, Shui IM, Rider JR, Epstein MM, Meisner A, Kenfield SA, Martin NE, Nguyen PL, Kantoff PW, Giovannucci EL, Stampfer MJ, Mucci LA. A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin Cancer Res. 2013 Mar 15; 19(6):1612-9.
-
Lai JJ, Chang P, Lai KP, Chen L, Chang C. The role of androgen and androgen receptor in skin-related disorders. Arch Dermatol Res. 2012 Sep; 304(7):499-510.
-
Rehman Y, Rosenberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther. 2012; 6:13-8.